The Citizen (KZN)

Aspen sells thrombosis drug


Drugmaker Aspen Pharmacare has agreed to sell the rights to its European thrombosis business to US pharmaceut­ical company Mylan for almost €642 million (about R12.8 billion).

“The transactio­n supports Aspen’s strategy of continuing to reshape the Group towards a greater concentrat­ion of revenue in emerging markets,” Aspen said. –

Newspapers in English

Newspapers from South Africa